Axalbion SA
🇨ðŸ‡Switzerland
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Private
- Established
- 2017-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://axalbion.com
A Study of Efficacy and Safety of AX-8 in Chronic Cough
Phase 2
Recruiting
- Conditions
- Chronic Cough
- Interventions
- Drug: AX-8, Part 1 of the studyDrug: AX-8, Part 2 of the studyDrug: Placebo, Part 1 of the studyDrug: Placebo, Part 2 of the study
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Axalbion SA
- Target Recruit Count
- 100
- Registration Number
- NCT04866563
- Locations
- 🇬🇧
Axalbion Study Site 4417, Orpington, England, United Kingdom
🇬🇧Axalbion Study Site 4406, Birmingham, England, United Kingdom
🇬🇧Axalbion Study Site 4404, Broughton, England, United Kingdom
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: AX-8 Part 1Drug: AX-8 Part 2
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Axalbion SA
- Target Recruit Count
- 20
- Registration Number
- NCT04107441
- Locations
- 🇬🇧
Medicines Evaluation Unit (MEU) Ltd, Manchester, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath